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Objective. Data from randomized clinical trials with metabolic outcomes can be used to address concerns about potential issues
of cardiovascular safety for newer drugs for type 2 diabetes. This meta-analysis was designed to assess cardiovascular safety of
GLP-1 receptor agonists. Design and Methods. MEDLINE, Embase, and Cochrane databases were searched for randomized trials of
GLP-1 receptor agonists (versus placebo or other comparators) with a duration ≥12 weeks, performed in type 2 diabetic patients.
Mantel-Haenszel odds ratio with 95% confidence interval (MH-OR) was calculated for major cardiovascular events (MACE), on
an intention-to-treat basis, excluding trials with zero events. Results. Out of 36 trials, 20 reported at least one MACE. The MH-
OR for all GLP-1 receptor agonists was 0.74 (0.50–1.08), P = .12 (0.85 (0.50–1.45), P = .55, and 0.69 (0.40–1.22), P = .20, for
exenatide and liraglutide, resp.). Corresponding figures for placebo-controlled and active comparator studies were 0.46 (0.25–
0.83), P = .009, and 1.05 (0.63–1.76), P = .84, respectively. Conclusions. To date, results of randomized trials do not suggest any
detrimental effect of GLP-1 receptor agonists on cardiovascular events. Specifically designed longer-term trials are needed to verify
the possibility of a beneficial effect.
1. Introduction
Cardiovascular safety is a growing concern for drugs used
for chronic conditions, such as diabetes. Among glucose-
lowering agents, sulfonylureas [1, 2], insulin [3, 4], and thia-
zolidinediones [5–7], have been suspected of adverse car-
diovascular effects, although some of those preoccupations
have not been confirmed [8–11]. Following these concerns,
the Food and Drug Administration issued a guidance for
companies submitting new chemical entities as treatments
for type 2 diabetes, requiring that, either in phase II-III trials,
or in a subsequent phase IV specifically designed randomized
clinical trial, a sufficient amount of information is collected
so as to exclude a risk increase of over 30% (i.e., the upper
limit—two-sided—of 95% confidence interval for major
cardiovascular events, in comparison with placebo and/or
other treatments, should not exceed 1.30; http://www.fda
.gov/downloads/Drugs/GuidanceComplianceRegulatoryInf-
ormation/Guidances/UCM071627.pdf).
Two GLP-1 receptor agonists (exenatide and liraglutide)
have been approved for human use, and several others are
currently under clinical development. It has been observed
that chronic stimulation of GLP-1 receptors could produce
beneficial effects on several cardiovascular risk factors [12];
furthermore, preliminary data on humans suggest that GLP-
1 could have direct effects on myocardial function [13].
However, no major trial assessing the effects of GLP-1
receptor agonists on cardiovascular morbidity and mortality
is available to date, nor will it be for a few years. In the mean-
time, the information on incident cases recorded as adverse
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Figure 1: Trial flow diagram. RCT: randomized clinical trial; T2: type 2.
events during trials designed for metabolic endpoints could
provide some hints on the possible cardiovascular profile of
these drugs. This meta-analysis was designed to assess the
effect of GLP-1 receptor agonists, compared with placebo or
active hypoglycemic drugs, on major cardiovascular events
in type 2 diabetic patients, as derived from randomized
controlled trials.
2. Research Design and Methods
2.1. Data Sources and Searches. An extensive Medline,
Embase, and Cochrane database search for “exenatide,” “lira-
glutide,” “albiglutide,” “taspoglutide,” “lixisenatide,” and
“semaglutide” was performed, collecting all randomized cli-
nical trials on humans up to November 1th, 2010. The identi-
fication of relevant abstracts, the selection of studies based on
the criteria described above, and the subsequent data extrac-
tion were performed independently by two of the authors
(E. Mannucci and M. Monami), and conflicts resolved by
the third investigator (N. Marchionni). Completed but still
unpublished trials were identified through a search of http://
www.clinicaltrials.gov/ website. Food and Drug Administra-
tion (FDA, http://www.fda.gov/) and European Medicines
Agency (EMEA, http://www.ema.europa.eu/) reviews of ap-
proved drugs, as well as published information provided to
FDA in response to queries during the approval process, were
also searched for retrieval of unpublished trials.
2.2. Study Selection. A meta-analysis was performed includ-
ing all randomized clinical trials with a duration of at least
12 weeks, either with a cross-over or a parallel series design,
enrolling patients with type 2 diabetes, comparing glucagon-
like peptide-1 (GLP-1) receptor agonists with placebo or
active drugs (oral hypoglycemic agents and/or insulin)
of other classes. Trials enrolling nondiabetic, or type 1
diabetic, subjects were also excluded. No review protocol was
published elsewhere.
2.3. Data Extraction and Quality Assessment. Results of
unpublished trials (characteristics of patients enrolled, treat-
ments, and major cardiovascular events) were retrieved, if
available, on http://www.clinicaltrials.gov/, http://www.no-
vonordisk-trials.com/website/content/trial-results.aspx, http:
//www.lillytrials.com/results/results.html, or http://www.cl-
inicalstudyresults.org/; Food and Drug Administration
(FDA, http://www.fda.gov/) and EuropeanMedicines Agency
(EMEA, http://www.ema.europa.eu/) reviews of approved
drugs, as well as published information provided to FDA in
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Table 1: Characteristics of the unpublished and undisclosed studies.
Study
Number of
patients
planned
Comparator Add-on to
Trial duration
(wks)
Design Study end date∗ Sponsor
Exenatide
NCT00434954 488 Aspart Metformin 26 PS, DB August 2009 Amylin
Liraglutide
NCT00696657 415 Placebo None 12 PS, DB February 2009 Novo
Taspoglutide
NCT00809705 60 Placebo None 12 PS, DB February 2010 Hoff-Roche
PS: parallel series; DB: double blind; Hoff. Roche: Hoffman-La Roche; Novo: Novo Nordisk.
Study name Statistics for each study MH odds ratio and 95% CI
MH odds
ratio
Upper
limit
Lower
limit
1.833 0.667 5.036 1.176 .24
1.588 0.376 6.713 0.629 .529
2.555 0.4911 3.304 1.114 .265
0.983 0.136 7.096 −0.017 .986
3 0.122 74.023 0.672 .502
0.652 0.144 2.954 −0.556 .579
0.244 0.022 2.704 −1.15 .25
0.497 0.099 2.492 −0.85 .396
0.494 0.082 2.976 −0.769 .442
0.496 0.069 3.542 −0.699 .484
1.523 0.059 39.477 0.253 .8
1.054 0.633 1.756 0.203 .839
0.501 0.174 1.445 −1.279 .201
0.822 0.193 3.503 −0.265 .791
0.053 0.003 1.042 −1.933 .053
0.243 0.04 1.469 −1.541 .123
0.245 0.022 2.728 −1.144 .253
0.25 0.022 2.787 −1.127 .26
0.497 0.031 8.043 −0.492 .623
0.329 0.013 8.119 −0.68 .497
2.017 0.113 36.059 0.477 .633
1.485 0.06 36.644 0.242 .809
0.145 0.007 2.823 −1.275 .202
2.35 0.121 45.668 0.564 .572
0.344 0.014 8.500 −0.652 .514
0.459 0.255 0.826 −2.599 .009
0.737 0.501 1.083 −1.552 .121
0.01 0.1 1 10 100
Versus active comparators (overall)
Versus placebo (overall)
Overall
Fav ours GLP-1RA Fav ours comparator
Z value P value
Nauck et al. [31]
Heine et al. [34]
Russell-Jones# et al. [44]
NCT00360334 et al. [33]
Diamant et al. [36]
NCT00393718 et al. [33]
Pratley et al. [50]
Nauck# et al. [47]
NCT00614120 et al. [33]
Garber et al. [49]
Davis et al. [37]
Kendall et al. [28]
Russell-Jones et al. [44]
Rosenstock et al. [17]
Marre et al. [46]
Buse et al. [27]
DeFronzo et al. [26]
Kaku et al. [43]
Gao et al. [21]
Nauck et al. [47]
Zinman et al. [45]
Bergenstal et al. [39]
Marre# et al. [46]
Bergenstal et al. [39]#
Figure 2: Effect of GLP-1 receptor agonists on fatal and nonfatal major cardiovascular events (MACE). Forest plot of individual studies.
GLP-1 RA: glucagon-like peptide-1 receptor agonists. #Studies with multiple comparators.
response to queries during the approval process, were also
searched for retrieval of unpublished information. All those
sources were also used to complete information on results of
published trials, when not reported in publications. For all
published trials, results reported in papers were used as the
primary source of information, when available.
The quality of trials was assessed using some of the
parameters proposed by Jadad et al. [14]. The score was not
used as a criterion for the selection of trials whereas some
items were used only for descriptive purposes.
2.4. Data Synthesis and Analysis. The principal outcome was
the effect of GLP-1 receptor agonists, compared with other
hypoglycemic agents or placebo, on major cardiovascular
events (MACE) as defined in the list provided by FDA for this
purpose (http://www.fda.gov/downloads/AdvisoryCommit-
tees/CommitteesMeetingMaterials/Drugs/Endocrinologica-
ndMetabolicDrugsAdvisoryCommittee/UCM148659.pdf),
including cardiovascular death, nonfatal myocardial infarc-
tion and stroke, and hospitalizations due to acute coronary
syndromes and/or heart failure.
Predefined separate analyses were performed for trials
with different GLP-1 receptor agonists, whenever possible.
Mantel-Haenszel odds ratio with 95% confidence inter-
val (MH-OR) was calculated for each of the events defined
above, on an intention-to-treat basis, excluding trials with
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Table 2: Characteristics of the studies included in the meta-analysis.
Study∗ (ref.)
NCT/FDA-
reference
Add-on to
Description of
randomization
Description of
allocation
Description of
blinding
Reporting of
drop-out
Intention-
to-treat
Albiglutide versus placebo
Rosenstock et al. [19] NCT00518115 None/Metf. NA NA A A Yes
Exenatide versus placebo
Gill et al. [20] NCT00516074 Metf./TZD NA NA A A Yes
Kadowaki et al. [21] NCT00382239 Sulfonylurea A NA A A Yes
Zinman et al. [22] NCT00099320 TZD A A A A Yes
Gao et al. [23] NCT00324363 SU + Metf. A NA A A Yes
DeFronzo et al. [24] NCT00135330 Rosiglitazone A NA OL A Yes
Apovian et al. [25] NR Multiple A A A A Yes
Moretto et al. [26] NCT00381342 None A A A A Yes
Liutkus et al. [27] NR
Metf/TZD +
Met
A A A A Yes
DeFronzo et al. [28] NCT00039013 Metformin A NA A A Yes
Buse et al. [29] NCT00039026 Sulfonylurea A NA A A Yes
Kendall et al. [30] NCT00035984 SU + Metf. NA NA A A Yes
Exenatide versus rosiglitazone
DeFronzo# et al. [24] NCT00135330 None A NA OL A Yes
Exenatide versus glibenclamide
Derosa et al. [31] NCT00135330 None A NA OL A Yes
Exenatide versus BiAsp 30/70
Bergenstal et al. [32] NCT00097877 SU + Metf. A A OL A Yes
Nauck et al. [33] NCT00082407 SU + Metf. A A OL A Yes
Exenatide versus glargine
Barnett et al. [34] NCT00099619 SU + Metf. A A OL A Yes
NCT00360334 [35] NCT00360334 OAD NR NR OL A Yes
Heine et al. [36] NCT00082381 SU + Metf. A A OL A Yes
Bunck et al. [37] NCT00097500 Metformin A NA OL A Yes
Diamant et al. [38] NCT00641056
SU +
Metf./Metf
A A OL A Yes
Exenatide versus insulin
Davis et al. [39] NCT00099333 SU/Metf. NA NA OL A Yes
Exenatide LAR versus placebo
Kim et al. [40] NCT00103935 Metf./None A A A A Yes
Exenatide LAR versus pioglitazone
Bergenstal et al. [41] NCT00637273 None A A A A Yes
Exenatide LAR versus sitagliptin
Bergenstal et al. [41]# NCT00637273 None A A A A Yes
Liraglutide versus placebo
Madsbad et al. [42] FDA 1310 None NA NA A A Yes
Vilsbøll [43] NCT00154401 None NA NA A A Yes
Seino et al. [44] FDA 1334 None A A A A Yes
Kaku et al. [45] NCT00395746 Sulfonylurea NA NA NA NA Yes
Russell-Jones et al. [46] NCT00331851 SU + Metf. A A A A Yes
Zinman et al. [47] NCT00333151 Metf. + TZD A A A A Yes
Marre et al. [48] NCT00318422 Sulfonylurea NA NA A A Yes
Nauck et al. [49] NCT00318461 Metformin A A A A Yes
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Table 2: Continued.
Study∗ (ref.)
NCT/FDA-
reference
Add-on to
Description of
randomization
Description of
allocation
Description of
blinding
Reporting of
drop-out
Intention-
to-treat
Liraglutide versus metformin
Feinglos et al. [50] NR None NA NA NA A No
Liraglutide versus rosiglitazone
Marre# et al. [48] NCT00318422 Sulfonylurea NA NA A A Yes
Liraglutide versus glimepiride
Madsbad# et al. [42] NR None NA NA OL A Yes
NCT00614120 [35] NCT00614120 Metformin NR NR OL NR NR
Nauck# et al. [49] NCT00318461 Metformin A A OL A Yes
Garber et al. [51] NCT00294723 None A A OL A Yes
Liraglutide versus glibenclamide
NCT00393718 [35] NCT00393718 None NR NR OL NR NR
Liraglutide versus sitagliptin
Pratley et al. [52] NCT00700817 None A A OL A Yes
Liraglutide versus glargine
Russell-Jones# et al. [46] NCT00331851 SU + Metf. A A A A Yes
∗
All the studies are multicenter and designed as parallel series, with the exception of NCT00099619 which is a cross-over trial; #studies with multiple
comparators. Metf.: metformin; NA: not adequate or not adequately reported; A: adequate; TZD: thiazolidinediones; TZD + Met.: thiazolidinediones +
metformin; SU + Metf.: sulfonylureas and metformin; OL: open-label; OAD: oral antidiabetic drugs; NR: not reported; SU/Metf: sulfonylureas or metformin;
LAR: long-acting release.
zero events. A random effect model was used because of
the impossibility of a reliable assessment of heterogeneity,
due to the small number of events in each trial [15].
Publication bias was not assessed, considering that the small
number of adverse cardiovascular events in each study was
irrelevant for the decision to publish trials with metabolic
endpoints. The main expected bias is represented by the fact
that the trials included were designed for noncardiovascular
(metabolic) endpoint; this means that cardiovascular events
were reported only as adverse events, without any system-
atic screening or predefined diagnostic criteria. The meta-
analysis was reported following the PRISMA checklist [16].
All analyses were performed using Comprehensive Meta-
analysis Version 2, Biostat (Englewood, NJ, USA) and SPSS
16.0.
This research was performed independently of any fund-
ing, as part of the institutional activity of the investigators.
3. Results
The trial flow is summarized in Figure 1. A total of 36 trials, 3
of which unpublished, were retrieved. Information on major
cardiovascular events was reported in 33 trials, 20 of which
with at least one event. The analysis on MACE was therefore
performed on 20 trials, enrolling 6,490 and 3,995 patients
(3.467 and 2.172 patient∗ years) in the GLP-1 receptor
agonist and comparator groups, respectively. The charac-
teristics of the retrieved trials, and of those which resulted
to be complete but were undisclosed, or did not report
information onMACE, are summarized in Tables 1, 2, and 3.
The total number of patients with events was 65 (0.01%)
and 49 (0.01%) in the GLP-1 receptor agonists and compara-
tor groups, respectively. Treatment with the experimental
drugs was not associated with an increased incidence of
MACE (MH-OR.0.74 (0.50–1.08); P = .12). A significant
reduction of cardiovascular events with GLP-1 receptor
agonists was observed in placebo-controlled trials but not in
studies versus active comparators (Figure 2). No consistent
pattern suggesting differences between exenatide and liraglu-
tide emerged across analyses. In comparisons with insulin (5
trials with events) and sulfonylureas (4 trials with events), the
MH-OR for GLP-1 receptor agonists was 1.77 (0.91–3.44),
P = .09, and 0.49 (0.22–1.10), P = .085, respectively.
All-cause mortality was reported in 33 trials, 9 of which
with at least one event (8 and 7) in GLP-1 receptor agonists
and comparator, respectively; MH-OR for experimental
drugs was 0.67 [0.26–1.78], P = .43.
4. Conclusions
The reduction of cardiovascular morbidity and mortality
is one of the main aims of long-term treatment of
hyperglycemia in type 2 diabetes. Therefore, the possibility
of an increased cardiovascular risk associated with some
hypoglycemic treatments [1, 3–7] is almost paradoxical.
Although some data on adverse cardiovascular effects
of specific drugs were not confirmed by subsequent
investigations [8–11], the concerns of health authorities
about the safety of new compounds appear to be justified
(http://www.fda.gov/downloads/Drugs/GuidanceComplian-
ceRegulatoryInformation/Guidances/UCM071627.pdf).
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Table 3: Moderators and outcome variables in individual studies included in the meta-analysis.
Study (ref.)
Number of
patients
(ID/C)
Trial
duration
(wks)
Age (ys)
Duration of
DM (ys)
HbA1c/FPG
baseline
(%/mmol/L)
BMI
baseline
(Kg/m2)
MACE
(n,ID/C)
All-cause
mortality
(n,ID/C)
Cardiovasc.
mortality
(n,ID/C)
Albiglutide versus placebo
Rosenstock et al. [19] 128/50 16 54 5 8.0/9.7 32.0 0/3 NR/NR NR/NR
Exenatide versus placebo
Gill et al. [20] 27/25 12 55 NR 7.3/NR NR 0/0 0/0 0/0
Kadowaki et al. [21] 115/40 12 59 11 8.0/9.1 25.9 0/0 0/0 0/0
Zinman et al. [22] 121/112 16 56 8 7.9/8.9 34.0 0/0 0/0 0/0
Gao et al. [23] 234/232 16 55 8 8.3/9.3 26.2 0/1 0/0 0/0
DeFronzo et al. [24] 47/45 20 56 NR 7.9/NR NR 0/0 0/0 0/0
Apovian et al. [25] 96/98 24 55 5 7.6/8.6 33.7 0/0 0/0 0/0
Moretto et al. [26] 155/77 24 54 1 7.8/8.7 31.5 0/0 0/0 0/0
Liutkus et al. [27] 111/54 26 54 6 8.2/9.1 33.5 0/0 0/0 0/0
DeFronzo et al. [28] 223/113 30 53 6 8.2/9.4 34.0 1/2 0/0 0/0
Buse et al. [29] 248/123 30 55 6 8.6/10.3 33.5 1/2 0/0 0/0
Kendall et al. [30] 486/247 30 55 9 8.5/9.9 34.0 7/6 0/1 0/1
Exenatide versus rosiglitazone
DeFronzo# et al. [24] 45/45 20 56 NR 7.9/NR NR 0/0 0/0 0/0
Exenatide versus glibenclamide
Derosa et al. [31] 63/65 52 56 NR 8.8/7.9 28.6 NR/NR 0/0 0/0
Exenatide versus BiAsp 30/70
Bergenstal et al. [32] 124/248 24 52 NR 10.1/11.4 33.8 NR/NR 0/1 0/1
Nauck et al. [33] 253/248 52 58 10 8.6/11.1 30.4 10/5 2/1 1/1
Exenatide versus glargine
Barnett et al. [34] 138/138 16 55 7 8.9/12.0 31.3 0/0 0/0 0/0
NCT00360334 [35] 118/116 26 56 NR 8.6/10.8 34.1 2/2 NR/NR NR/NR
Heine et al. [36] 282/267 26 59 9 8.2/10.2 31.3 5/3 0/0 0/0
Bunck et al. [37] 36/33 52 58 5 7.5/9.1 30.6 NR/NR NR/NR NR/NR
Diamant et al. [38] 233/232 26 58 8 8.3/9.8 32.0 1/0 0/0 0/0
Exenatide versus insulin
Davis et al. [39] 33/16 16 53 11 8.1/8.7 34.0 1/0 0/0 0/0
Exenatide LAR versus placebo
Kim et al. [40] 30/14 15 53 4 8.4/10.7 36.0 0/0 0/0 0/0
Exenatide LAR versus pioglitazone
Bergenstal et al. [41] 160/165 26 52 6 8.5/9.1 32.0 0/3 0/0 0/0
Exenatide LAR versus sitagliptin
Bergenstal et al. [41]# 160/166 26 52 6 8.5/9.1 32.0 0/1 0/1 0/0
Liraglutide versus placebo
Madsbad et al. [42] 135/29 12 57 4 7.5/NR 30.4 0/0 0/0 0/0
Vilsbøll [43] 123/40 14 56 4 8.3/11.8 30.1 0/0 0/0 0/0
Seino et al. [44] 180/46 14 57 8 8.3/NR 23.9 0/0 0/0 0/0
Kaku et al. [45] 176/88 24 60 10 8.4/NR 24.9 1/1 0/0 0/0
Russell-Jones et al. [46] 232/115 26 57 9 8.3/9.2 30.6 5/1 1/2 0/2
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Table 3: Continued.
Study (ref.)
Number of
patients
(ID/C)
Trial
duration
(wks)
Age (ys)
Duration of
DM (ys)
HbA1c/FPG
baseline
(%/mmol/L)
BMI
baseline
(Kg/m2)
MACE
(n,ID/C)
All-cause
mortality
(n,ID/C)
Cardiovasc.
mortality
(n,ID/C)
Zinman et al. [47] 355/175 26 55 9 8.5/10.1 33.7 1/0 0/0 0/0
Marre et al. [48] 695/114 26 56 6 8.4/9.7 29.7 3/2 0/0 0/0
Nauck et al. [49] 724/121 26 57 7 8.4/10.0 31.2 6/0 1/0 0/0
Liraglutide versus metformin
Feinglos et al. [50] 176/34 12 53 5 7.0/NR 34,5 0/0 0/0 0/0
Liraglutide versus rosiglitazone
Marre# et al. [48] 695/232 26 56 6 8.4/9.7 29.7 3/0 0/0 0/0
Liraglutide versus glimepiride
Madsbad# et al. [42] 135/26 12 57 4 7.5/NR 30.4 0/0 0/0 0/0
NCT00614120 [35] 698/231 16 53 7 NR/NR 25.5 3/2 0/0 0/0
Nauck# et al. [49] 724/121 26 57 7 8.4/10.0 31.2 6/2 1/0 0/0
Garber et al. [51] 498/248 52 53 5 8.3/9.4 33.0 2/2 0/1 0/0
Liraglutide versus glibenclamide
NCT00393718 [35] 268/132 24 58 8 8.3/NR 24.8 4/3 1/0 0/0
Liraglutide versus sitagliptin
Pratley et al. [52] 446/219 26 55 6 8.4/10.0 32.8 1/1 1/1 0/1
Liraglutide versus glargine
Russell-Jones# et al. [46] 232/234 26 57 9 8.3/9.2 30.6 5/1 1/1 0/1
#
Studies with multiple comparators; DM: diabetes mellitus; FPG: fasting plasma glucose; MACE: major cardiovascular events; cardiovasc.: cardiovascular;
NR: not reported.
In order to reach definitive conclusions on cardiovascular
safety of any drug, large-scale, long-term trials should be
performed prior to marketing; unfortunately, this effort
would be economically unfeasible for pharmaceutical com-
panies. The FDA accepted a compromise, allowing the
organization of such trials after drug approval, as a condition
for the maintenance of marketing authorization. The limit of
this approach is that cardiovascular safety of new drugs will
be established only several years after their approval, leaving
clinicians without reliable information on this critical point
in the meantime.
Meta-analyses of cardiovascular events recorded as
adverse events in randomized clinical trials designed for
other purposes can represent an additional source of infor-
mation. This approach has several limitations, most notably
the lack of predefined diagnostic criteria and screening
methods for incident cardiovascular disease, with the risk
of misdiagnosis and underdiagnosis. It should also be
recognized that in some of the trials included, cardiovascular
events were reported only as adverse events, without being
prospectively adjudicated. Moreover, the limited duration
of trials designed for metabolic purposes can impair their
ability to detect longer-term effects on atherogenesis. Fur-
thermore, the meta-analysis of small trials with few events
each poses some specific, and complex, statistical problems
[17]. All these limitations affected the reliability of results
of some meta-analyses [6, 7] on cardiovascular safety of
hypoglycemic drugs [10, 17, 18].
Those considerations should be taken into account when
interpreting the results of the present meta-analysis, which
exclude, at least in the short term, any major adverse effect of
GLP-1 receptor agonists on cardiovascular morbidity. Inter-
estingly, those drugs, as a class, are below to the 1.3 threshold
chosen by the FDA for the upper limit of 95% confidence
interval to establish the cardiovascular safety of a new drug.
Interestingly, a significant reduction of cardiovascular
morbidity with GLP-1 receptor agonists was observed in
comparison with placebo. This result should be discussed
with great caution, considering the limitations highlighted
above; in fact, a meta-analysis of trials performed for
different (noncardiovascular) endpoints provides reliable
information on safety, but not on efficacy. Speculatively, sev-
eral mechanisms could underlie a beneficial effect of GLP-1
receptor agonists on cardiovascular risk. Reduction of blood
glucose, body weight, and blood pressure, as well as favorable
effects on lipid profile, have all been reported. Direct
myocardial effects of GLP-1 receptor stimulation could
theoretically reduce the functional impact of myocardial
ischemia [13], leading to clinical improvements. However,
the possibility of a beneficial action of GLP-1 receptor
agonists on cardiovascular events should be confirmed
through specifically designed randomized clinical trials.
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In conclusion, GLP-1 receptor agonists do not appear
to increase cardiovascular morbidity in comparison with
placebo or other active drugs. Any possible beneficial action
should be assessed in further trials.
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